Fly News Breaks for August 16, 2017
Aug 16, 2017 | 16:13 EDT
Evercore ISI analyst Josh Schimmer initiated AbbVie with an Outperform and a $95 price target.
News For ABBV From the Last 2 Days
Jan 25, 2021 | 08:35 EST
Alector (ALEC) has dosed the first participant in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer's disease. AL002 is an investigational, humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2, a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia, which serve as the immune cells in the brain. The AL002 clinical program is being developed in collaboration with AbbVie (ABBV). Research suggests that reduction of TREM2 functionality may lead to Alzheimer's disease and other forms of dementia. Increasing TREM2 activity in the brain may prove to be an effective therapeutic approach by activating the brain's immune system to target multiple pathologies that are present in Alzheimer's disease, rather than a single pathology.